Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast Limited has announced the quotation of 3,095,000 fully paid ordinary securities on the Australian Securities Exchange, effective January 22, 2025. This development follows previous market transactions and may influence Mesoblast’s market presence by potentially increasing liquidity and shareholder engagement, while providing further resources for its ongoing projects and strategic initiatives.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company primarily focused on developing regenerative medicine products. The company specializes in cellular medicines targeting conditions such as cardiovascular diseases, inflammatory ailments, and orthopedic disorders, with a market focus on delivering innovative therapies to enhance health outcomes.
YTD Price Performance: 5.45%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.19B
Learn more about MSB stock on TipRanks’ Stock Analysis page.
